TriSalus Life Sciences, Inc. develops oncology-focused drug-delivery technology and an investigational immunotherapy program for solid tumors. Its Pressure-Enabled Drug Delivery, or PEDD, platform is used through the TriNav Infusion System in interventional radiology procedures, including TARE and TACE, for primary liver cancer and liver metastases.
Company news centers on TriNav commercial performance, clinical and preclinical data for PEDD, studies in liver tumors, research involving nelitolimod, and presentations to interventional radiology audiences. Updates also include quarterly financial results, revenue guidance, capital actions, shareholder voting matters and governance changes tied to the company’s oncology technology strategy.
TriSalus Life Sciences (Nasdaq: TLSI) will host a conference call and webcast on Tuesday, May 12, 2026 at 4:30 PM ET to discuss first quarter 2026 financial results for the quarter ended March 31, 2026. A press release with results will be issued before the call.
Dial-in registration is required; webcast and replay will be available on the company investor relations website.
TriSalus Life Sciences (Nasdaq: TLSI) will present new clinical and preclinical data at the SIR 2026 Annual Scientific Meeting April 11–15, 2026 in Toronto. Presentations on April 13–14 showcase the Pressure Enabled Drug Delivery™ (PEDD™) platform across liver, pancreatic and uterine applications.
The company highlighted investigator and preclinical work and noted nearing completion of multiple Phase 1 data sets and upcoming partnership discussions.
TriSalus Life Sciences (Nasdaq: TLSI) appointed Richard Marshall, M.D., as Chief Medical Officer, effective June 29, 2026. Dr. Marshall transitions from Medical Director (since January 2025) and will lead medical strategy, clinical development, evidence generation and broader strategic initiatives for the company’s PEDD platform and TriNav product suite.
The appointment signals continued leadership strengthening as TriSalus pursues clinical and economic advantages for its pressure-enabled drug delivery approach across solid tumors.
TriSalus Life Sciences (Nasdaq: TLSI) published preclinical data showing that Pressure-Enabled Drug Delivery (PEDD) with the TriNav® Infusion System improved intratumoral distribution and immune activation of nelitolimod in liver tumor models.
Key findings include greater tumor distribution versus microcatheter delivery, reduced myeloid-derived suppressor cells, increased CD8+ T cell infiltration, and reduced tumor growth in murine metastasis models.
TriSalus (Nasdaq: TLSI) reported strong commercial growth in Q4 2025 with $13.2M revenue (+60% y/y) and full-year $45.2M revenue (+53% y/y). The company raised $46M gross proceeds in a public offering, improved adjusted EBITDA, and reaffirmed 2026 revenue guidance of $60–62M.
Management cited product launches, expanded TriNav adoption, and planned commercial investments to support 2026 growth and broader PEDD platform adoption.
TriSalus Life Sciences (Nasdaq: TLSI) will host a conference call and webcast on Thursday, March 5, 2026 at 4:30 PM Eastern to discuss financial results for the quarter ended December 31, 2025. A press release with results will be issued before the call.
Participants can register for phone access and the webcast; a replay will be available on the investor relations website after the event.
TriSalus Life Sciences (Nasdaq: TLSI) priced an underwritten public offering of 9,756,100 common shares at $4.10 per share, with gross proceeds of approximately $40.0 million.
The company granted the underwriter a 30-day option to purchase up to 1,463,415 additional shares (15%). The offering is expected to close on or about February 23, 2026, subject to customary closing conditions.
TriSalus Life Sciences (Nasdaq: TLSI) announced its intent to sell shares of common stock in an underwritten public offering, with all shares to be sold by the company. TriSalus intends to grant underwriters a 30-day option to purchase up to 15% of the offering.
Lake Street Capital Markets is the sole book-runner. The offering is made from an effective Form S-3 shelf registration (File No. 333-291509) declared effective December 4, 2025, and is subject to market conditions; final terms will be disclosed in a prospectus supplement.
TriSalus Life Sciences (Nasdaq: TLSI) announced a board change effective February 4, 2026: Dr. Arjun “JJ” Desai resigned and Michael P. Stansky was appointed to the Board.
Mr. Stansky brings 40 years of investment and healthcare experience, prior roles at Tudor Investment and Wellington, current board seats at Insightec and Momentis Surgical, and credentials as a CPA and CFA.
TriSalus Life Sciences (Nasdaq: TLSI) reported preliminary unaudited results for Q4 and full-year 2025. Q4 2025 revenue was approximately $13.2 million (≈60% YoY) and full-year 2025 revenue was approximately $45.2 million (≈53% YoY), exceeding 2025 guidance. Year-end cash and cash equivalents were approximately $20.4 million, down $2.3 million from the start of Q4. The company set initial 2026 revenue guidance of approximately $60–$62 million. Results are preliminary, unaudited and subject to change pending year-end close and audit.